Skip to content
doubtly

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic
infusion of genetically engineered lymphocytes because:
1) Retroviral vector is introduced into these lymphocytes
2) Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages
3) Lymphocytes from patient’s blood are grown in culture, outside the body.
4) Genetically engineered lymphocytes are not immortal cells.
Doubtly Asked Student doubt Save WhatsApp Report

1 answer

Your answer

Log in or create a free account to answer this question.